Arrowhead Pharmaceuticals Inc (FRA:HDP1)
€ 24.79 0.13 (0.53%) Market Cap: 3.07 Bil Enterprise Value: 2.91 Bil PE Ratio: 0 PB Ratio: 17.46 GF Score: 53/100

Arrowhead Pharmaceuticals Inc Pulmonary R&D Day Transcript

May 26, 2022 / 02:00PM GMT
Release Date Price: €31.53 (+0.46%)
Vincent Anzalone
Arrowhead Pharmaceuticals, Inc. - Head of IR & VP

I think for the last couple of years have been tough for everybody and coming back face-to-face and talking about all this new and exciting stuff going on at Arrowhead is really, really great. So thank you for joining us.

So safe harbor. So the obligatory slide, what we're going to be talking about today includes forward-looking statements. So please refer to all the risk factors in our SEC filings.

And here are our panelists. We've got a great group to talk to you guys today about our pulmonary platform and the 2 new pulmonary products, MUC5AC and RAGE and then our newest announced program today against MMP7 for IPF. So the external panelists are Dr. Mario Castro and Dr. Matthias Salathe, both from the University of Kansas Medical Center, both are experts in the field of muco-obstructive and inflammatory pulmonary disease. So we're very lucky to have them today.

From the company myself, Chris Anzalone, our CEO; Erik Bush, our Group Vice President of Biology; James Hamilton, our Senior Vice President of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot